## **Special Issue**

## Cardiovascular Disease Prevention in the Era of Personalized Medicine

### Message from the Guest Editor

Dear colleagues, Cardiovascular disease (CVD) is the leading cause of mortality worldwide. Prevention of CVD is based on the management of cardiovascular risk factors, including hypertension, dyslipidemia, diabetes mellitus, obesity, and smoking. Antiplatelet and anticoagulant treatment is also needed in certain subgroups. With the introduction of several novel pharmacological agents, personalized decisions can be made to optimize the safety and efficacy of the treatment of these risk factors. In this Special Issue, the management of the major modifiable cardiovascular risk factors is discussed. Given the multitude of therapeutic options, an evidence-based strategy is essential to reducing cardiovascular morbidity and mortality, particularly in high-risk patients with multiple comorbidities.

### **Guest Editor**

Dr. Konstantinos Tziomalos

First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 54636 Thessaloniki, Greece

### Deadline for manuscript submissions

closed (22 February 2022)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/57363

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





## Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



## **About the Journal**

### Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

#### Editor-in-Chief

#### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

#### **Author Benefits**

### **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

